NEW SPECIAL REPORT: FDA SAFETY NOTICE for Veozah
Dr. Chapa’s OBGYN Clinical Pearls
00:00
Urgent FDA Safety Report on Vioza: Liver Injury Precautions
This chapter provides a critical update on the FDA's safety communication regarding Fezzolinatant, known as Vioza, highlighting a rare but serious liver injury linked to the medication. It underscores the importance of monitoring, reporting adverse events, and the necessary actions healthcare providers must take to ensure patient safety.
Play episode from 00:00
Transcript
